Livzon Pharmaceutical Group Inc
SZSE:000513

Watchlist Manager
Livzon Pharmaceutical Group Inc Logo
Livzon Pharmaceutical Group Inc
SZSE:000513
Watchlist
Price: 37.92 CNY 0.72% Market Closed
Market Cap: 35B CNY
Have any thoughts about
Livzon Pharmaceutical Group Inc?
Write Note

Livzon Pharmaceutical Group Inc
Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Livzon Pharmaceutical Group Inc
Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Livzon Pharmaceutical Group Inc
SZSE:000513
Common Stock
ÂĄ926.3m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
12%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Common Stock
ÂĄ52k
CAGR 3-Years
0%
CAGR 5-Years
120%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Common Stock
ÂĄ603.3m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
14%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Common Stock
ÂĄ6.4B
CAGR 3-Years
0%
CAGR 5-Years
8%
CAGR 10-Years
16%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Common Stock
ÂĄ1.8B
CAGR 3-Years
12%
CAGR 5-Years
7%
CAGR 10-Years
6%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Common Stock
ÂĄ401m
CAGR 3-Years
4%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Livzon Pharmaceutical Group Inc
Glance View

Market Cap
35B CNY
Industry
Pharmaceuticals

Nestled within the bustling pharmaceutical landscape of China, Livzon Pharmaceutical Group Inc. has meticulously carved its path since its inception in 1985, blossoming into a formidable player in the industry. Based in Zhuhai, Guangdong Province, the company has steadily built a diversified portfolio across the pharmaceutical spectrum, focusing on both traditional Chinese medicine and modern biopharmaceutical products. Livzon leverages its robust research and development (R&D) capabilities to produce an extensive range of medications, catering primarily to major therapeutic areas such as cardiovascular, gastrointestinal, anti-infective, and oncology segments. With rigorous standards driving their production lines, they ensure premium quality, which has bolstered their reputation and allowed them to secure numerous patents and proprietary products. Livzon's revenue engine is fueled by its strategic blend of manufacturing prowess and a well-tuned distribution network. The company operates a comprehensive production chain, from raw material sourcing and pharmaceuticals manufacturing to extensive distribution channels stretching across domestic and global markets. It sustains strong collaborations with hospitals, medical institutions, and pharmacies, which facilitate widespread accessibility and market penetration. Additionally, Livzon invests heavily in innovation, aligning with global health demands through strategic partnerships and joint ventures, further pushing the boundaries of research. By balancing traditional medicinal wisdom with cutting-edge technologies, Livzon positions itself as an agile competitor in the ever-evolving pharmaceutical arena, continuously driving value creation and securing its foothold in the global marketplace.

Intrinsic Value
47.84 CNY
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Livzon Pharmaceutical Group Inc's Common Stock?
Common Stock
926.3m CNY

Based on the financial report for Sep 30, 2024, Livzon Pharmaceutical Group Inc's Common Stock amounts to 926.3m CNY.

What is Livzon Pharmaceutical Group Inc's Common Stock growth rate?
Common Stock CAGR 10Y
12%

Over the last year, the Common Stock growth was -1%.

Back to Top